Javelin Biotech and Pfizer Announce Landmark Publication Demonstrating Clinical PK Predictions Using Multi-Tissue Chip Platform

Javelin Biotech and Pfizer Announce Landmark Publication Demonstrating Clinical PK Predictions Using Multi-Tissue Chip Platform

Javelin Biotech today announced a landmark scientific publication, titled "Interconnected multi-microphysiological systems and PBPK modeling for predicting human pharmacokinetics”, in the "Breakthrough" special issue of Lab on a Chip. The study details a liver-centric multi-tissue chip (MTC) platform designed to capture the complex pharmacokinetic (PK) profiles of small-molecule drugs.

The research marks a significant demonstration of how combinatorial NAMs enable the translation of multi-MPS data into clinical exposure predictions. By integrating the liver MPS with kidney and skeletal muscle within a single, recirculating microfluidic environment, the platform allows for the simultaneous identification of hepatic metabolism, renal excretion, and volume of distribution.

“This work is a major achievement in the New Approach Methodologies (NAMs) space, proving that multi-MPS platforms can deliver accurate clinical predictions,” said Murat Cirit, Ph.D., Chief Executive Officer of Javelin Biotech. “Small molecules represent 50% of therapeutics in development today. On the first anniversary of the FDA Modernization Act 3.0, this study provides critical scientific evidence that the Javelin platform can deliver clinical predictions and accelerate development without the use of animal data.”